Vera Therapeutics Inc. (Class A) (VERA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, VERA scores 32 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -35% and an FCF yield of -10.99%. For a prospective investor, this indicates the business is currently consuming cash rather than generating it relative to its capital base.
• Whale 13F Flow: 6 / 20. The rating reflects institutional accumulation and options positioning, but the source data does not provide the underlying 13F holdings, so the composition of this signal cannot be verified here.
• Insider Conviction: 3 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar after Fundamental Cash Engine, and it points to weak insider-side conviction in the data provided.
• Macro Regime Fit: 6 / 20. The rating cites a Beta of 1.0 and sector sensitivity, indicating market-level volatility exposure without a clear defensive offset in the source data.
• Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5. The F-Score of 2/9 is a weak reading on the Piotroski scale and is a primary reason this pillar scores as it does.

Taken together, the rating frames VERA as a forensic-risk name: losses, negative cash flow, and a weak F-Score dominate the picture, with institutional and market-sensitivity signals providing limited offset. Upside drivers the data supports are the recent positive news flow and institutional interest; the valuation tradeoff is that a $2.2B market capitalization is being carried against negative ROIC and negative free cash flow, with no earnings per share or P/E figure in the source data to anchor valuation. Per the Roarable RQD rating, the overall stance is avoid.

Vera Therapeutics Inc. (Class A) (VERA) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Per the profile, the company carries a market capitalization of $2.2B. The source data does not identify its specific products, customers, or revenue model. Revenue is reported as $0.0M across the available periods.

Per the SEC financials, reported revenue is $0.0M in each period, and operating and net losses widened from FY 2023 through FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash rose from $92.6M in FY 2024 to $354.7M in FY 2025, while Debt/Equity is 0.5; the source data does not report a debt figure for any period.

• RISK WATCH (RED): Coverage on IgAN data raising the question of whether the mechanism is durable or crowded.
• CATALYST (GREEN): Coverage reporting an FDA approval for a rare kidney disease drug, with retail interest framing it as a catalyst.
• MARKET WIRE (YELLOW): Raymond James reiterated a Strong Buy on the kidney disease data.
• MARKET WIRE (YELLOW): Simply Wall St stock analysis.
• MARKET WIRE (YELLOW): TradingView estimates coverage.
• MARKET WIRE (YELLOW): Phase III IgA Nephropathy results for TRUTAKNA.

Per the news feed, the primary positive catalyst is the FDA approval and Phase III data in IgA nephropathy, while the sole red-flag item questions the durability of the mechanism. Per the Butterfly Supply-Chain Graph, no supply chain is identified (supply_chain: NONE), and no butterfly links or proprietary signals are present.

• What is the company's revenue model, given $0.0M reported revenue across all periods?
• What is the debt balance, since the source data reports Debt as N/A for every period?
• What is the composition of the institutional 13F and insider Form 4 flow underlying the Whale and Insider pillar scores?
• What is the current analyst consensus and price target coverage, given the analyst data is absent?
• What is the cash runway implied by the FY 2025 cash balance of $354.7M against the $-241.7M free cash flow?